

Simon A Hinke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11455058/publications.pdf>

Version: 2024-02-01

31
papers

1,409
citations

430874

18
h-index

580821

25
g-index

31
all docs

31
docs citations

31
times ranked

1301
citing authors

#	ARTICLE	IF	CITATIONS
1	Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors. <i>Diabetes</i> , 2004, 53, 1326-1335.	0.6	283
2	Dipeptidyl Peptidase IV-Resistant [D-Ala ²]Glucose-Dependent Insulinotropic Polypeptide (GIP) Improves Glucose Tolerance in Normal and Obese Diabetic Rats. <i>Diabetes</i> , 2002, 51, 652-661.	0.6	108
3	Metformin Effects on Dipeptidylpeptidase IV Degradation of Glucagon-like Peptide-1. <i>Biochemical and Biophysical Research Communications</i> , 2002, 291, 1302-1308.	2.1	108
4	Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2003, 284, E931-E939.	3.5	105
5	A novel pathway for regulation of glucose-dependent insulinotropic polypeptide receptor expression in Î²-cells. <i>FASEB Journal</i> , 2003, 17, 91-93.	0.5	89
6	AKAP150 Contributes to Enhanced Vascular Tone by Facilitating Large-Conductance Ca ²⁺ -Activated K ⁺ Channel Remodeling in Hyperglycemia and Diabetes Mellitus. <i>Circulation Research</i> , 2014, 114, 607-615.	4.5	86
7	Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP). <i>BBA - Proteins and Proteomics</i> , 2001, 1547, 143-155.	2.1	70
8	Anchored phosphatases modulate glucose homeostasis. <i>EMBO Journal</i> , 2012, 31, 3991-4004.	7.8	69
9	Metabolism of glucagon by dipeptidyl peptidase IV (CD26). <i>Regulatory Peptides</i> , 2001, 96, 133-141.	1.9	67
10	Plasticity of the Î² cell insulin secretory competence: preparing the pancreatic Î² cell for the next meal. <i>Journal of Physiology</i> , 2004, 558, 369-380.	2.9	61
11	Glucose-Dependent Insulinotropic Polypeptide Stimulation of Lipolysis in Differentiated 3T3-L1 Cells: Wortmannin-Sensitive Inhibition by Insulin**This work was supported by grants from Zymogenetics Inc. (Seattle, WA), the Medical Research Council of Canada (5â€“90007-RAP/CHSM) and the Canadian Diabetes Association (CHSM/RAP).. <i>Endocrinology</i> , 1999, 140, 398-404.	2.8	55
12	MyRIP Anchors Protein Kinase A to the Exocyst Complex. <i>Journal of Biological Chemistry</i> , 2007, 282, 33155-33167.	3.4	43
13	Characterization of the Carboxyl-terminal Domain of the Rat Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor. <i>Journal of Biological Chemistry</i> , 1999, 274, 24593-24601.	3.4	31
14	Structure-Function Analysis of a Series of Novel GIP Analogues Containing Different Helical Length Linkers. <i>Biochemistry</i> , 2003, 42, 3081-3088.	2.5	29
15	Prior in vitro exposure to GLP-1 with or without GIP can influence the subsequent beta cell responsiveness. <i>Biochemical Pharmacology</i> , 2004, 68, 33-39.	4.4	23
16	AKAP150 participates in calcineurin/NFAT activation during the down-regulation of voltage-gated K ⁺ currents in ventricular myocytes following myocardial infarction. <i>Cellular Signalling</i> , 2016, 28, 733-740.	3.6	23
17	Analogues of Glucose-Dependent Insulinotropic Polypeptide With Increased Dipeptidyl Peptidase IV Resistance. , 2000, 477, 187-195.		22
18	Glucose-Dependent Insulinotropic Polypeptide Stimulation of Lipolysis in Differentiated 3T3-L1 Cells: Wortmannin-Sensitive Inhibition by Insulin. <i>Endocrinology</i> , 1999, 140, 398-404.	2.8	22

#	ARTICLE	IF	CITATIONS
19	Structure-Activity Relationships of Glucose-Dependent Insulinotropic Polypeptide (GIP). Biological Chemistry, 2003, 384, 403-7.	2.5	20
20	In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide. Life Sciences, 2004, 75, 1857-1870.	4.3	19
21	[Ser2]- and [Ser(P)2]Incretin Analogs. Journal of Biological Chemistry, 2004, 279, 3998-4006.	3.4	17
22	Epac2: A Molecular Target for Sulfonylurea-Induced Insulin Release. Science Signaling, 2009, 2, pe54.	3.6	13
23	Glucose-dependent Insulinotropic Polypeptide (GIP): Development of DP IV-Resistant Analogues with Therapeutic Potential. , 2003, 524, 293-301.		12
24	On Combination Therapy of Diabetes With Metformin and Dipeptidyl Peptidase IV Inhibitors. Diabetes Care, 2002, 25, 1490-1491.	8.6	11
25	Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective". Biochemical and Biophysical Research Communications, 2002, 296, 229-232.	2.1	9
26	Diamyd, an alum-formulated recombinant human GAD65 for the prevention of autoimmune diabetes. Current Opinion in Molecular Therapeutics, 2008, 10, 516-25.	2.8	9
27	Inverse vaccination with islet autoantigens to halt progression of autoimmune diabetes. Drug Development Research, 2011, 72, 788-804.	2.9	4
28	Relative Contribution of Incretins to the Glucose Lowering Effect of DP IV Inhibitors in Type 2 Diabetes Mellitus (T2DM). , 2006, 575, 119-133.		1
29	Anchored phosphatases modulate glucose homeostasis. EMBO Journal, 2012, 31, 4481-4481.	7.8	0
30	AKAP150 is required for NFATc3-induced vascular BKCa channel suppression during diabetic hypertension. FASEB Journal, 2012, 26, 872.26.	0.5	0
31	AKAP150-dependent changes in K _v channel expression in ventricular myocytes following myocardial infarction. FASEB Journal, 2012, 26, 1053.9.	0.5	0